Protecting the Public - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Protecting the Public
Overt and covert packaging technologies evolve to authenticate drugs and fight counterfeits.


Pharmaceutical Technology
Volume 36, Issue 11

There have been some victories in the fight against counterfeit and gray market drugs. After admitting he distributed adulterated and counterfeit drugs, James Newcomb of La Jolla, CA, received a 24-month prison sentence from the US District Court for the Eastern District of Missouri. As part of the February 2012 plea deal, he also forfeited $1.4 million and a Land Rover (1).

Legal requirements


Hallie Forcinio
The US Congress, however, wants harsher punishment for offenses involving counterfeit drugs. Under the FDA Safety and Innovation Act, signed by President Obama in July 2012, the Attorney General shall give increased priority to efforts to investigate and prosecute these criminals. In addition, the US Sentencing Commission is to consider increased penalties for drug counterfeiting (2).

Meanwhile, regulators worldwide are working to protect consumers. In the European Union, the Falsified Medicines Directive 2011/62/EU takes effect on Jan. 2, 2013 (3). The Directive requires authentication features on individual prescription-drug packs to enable verification throughout the supply chain. It also strengthens requirements for control and inspection of manufacturers of active substances. Manufacturers also must report any suspicion of falsified medicines. Other provisions give penalties for the manufacturing, distribution, import, and export of falsified medicinal products and point out the dangers associated with sale of medicines via the Internet.

Regulatory initiatives

With a significant percentage of medicines purchased from Internet sites found to be counterfeit, FDA has embarked on a public education campaign, BeSafeRx: Know Your Online Pharmacy (4).

Another tool used by FDA is its October 2011 Guidance for Industry: Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting (5). FDA is also training field agents in the use of a handheld device to check for counterfeit products and packaging arriving at ports of entry. The CD3 (Counterfeit Detection Device #3) emits light in 10 wavelengths to check API and drug samples against stored scans. It also detects package tampering.

Other organizations are hard at work too. The World Health Organization’s (WHO) Working Group of Member States on Substandard/Spurious/Falsely-Labelled Falsified/Counterfeit Medical Products takes a three-pronged approach: education, norms and standards, and technical support to countries (6). WHO also supports the International Medical Products Anti-Counterfeiting Taskforce, a group it launched in 2006 with a wide range of partners including international organizations, nongovernmental organizations, enforcement agencies, pharmaceutical manufacturers’ associations, and drug and regulatory authorities.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here